AbbVie Inc.
Fused heterocyclic compounds as S1P modulators
Last updated:
Abstract:
The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
Status:
Grant
Type:
Utility
Filling date:
26 Aug 2016
Issue date:
11 Feb 2020